Prescribers with restrictions

Based on data from TPP Alberta, CPSA can impose prescribing conditions on physicians that restrict their prescriptive authority under certain situations. These listings and conditions are below.

Pharmacists can contact TPP Alberta using the contact form at the bottom of this page for guidance if questions arise or advice is required in specific circumstances.

Any prescribing condition effective before March 1st, 2021 does not include Antibiotics.

Physicians

Adams, James (Jim)

Date effective: Aug. 15, 2024

Restrictions:

Type 1 and Type 2 medications monitored by the Alberta Tracked Prescription Program except for stimulants for the treatment of ADD and ADHD, benzodiazepines, antibiotics, Z class drugs, Gabapentin and Pregabalin.

 

Restriction:

Restricted from prescribing all Type 1 and Type 2 medications monitored by the Alberta Tracked Prescription Program, excluding antibiotics. Exception: Alberta TPP medications, Type 1 and Type 2, prescriptions that included refills in the original prescription that were initiated prior to this restriction shall only be permitted until July 28, 2024. As of July 29, 2024, no exceptions shall apply and no prescription refills shall be permitted.

Alshigagi, Emadalden

Date effective: May 1, 2024

 

Barrow, John Lincoln

Date effective: May 31, 2024

 

Ben Milud Jalutha, Ben

Date effective: May 21, 2024

 

Restriction:

Restricted from prescribing OAT medications for the management of Opioid Use Disorder (with the exception of Buprenorphine/Naloxone).

 

Restriction:

No new Type 1 or Type 2 opioid prescriptions (may only refill chronic opioid prescriptions for current patients).

 

Restriction:

Prescribing restrictions apply. Prescribing restrictions for the following medications: Tracked Prescription Program medications, anabolic steroids, methylphenidate, barbiturates, codeine containing drugs, amphetamine or amphetamine like appetite suppressants, benzodiazepines and other anxiolytics, hypnotics and sedatives, and muscle relaxants.

 

Collett, Franklin Dean

Date effective: Nov. 29, 2019

 

Dulai, Gurjeet Singh

Date effective: March 27, 2020

Restrictions:

Restricted from prescribing TPP Alberta (Type 1) medications except for hospital inpatients, patients in a long-term care facility and immediate administration in the emergency department. Restricted from dispensing or administering TPP Alberta (Type 2) medications.

 

Han, William (Wei)

Date effective: Jan. 15, 2023

 

Hauptman, Robert

Date effective: July 8, 2024

Restrictions:

Restricted from prescribing all Type 1 and Type 2 medications monitored by the Alberta Tracked Prescription Program (TPP), and cannabinoids. Excludes antimicrobials.

Restrictions:

Restricted from prescribing All Alberta TPP medications Type 1, and Type 2, with the exclusion of antibiotics, gabapentinoids, stimulants and Orexin antagonists. Permitted to prescribe Alberta TPP medications Type 2 containing codeine or tramadol for the treatment of acute, episodic pain for up to fourteen (14) days per three-month period for patients already in Dr. Hauptman's practice panel.

 

Kordyban, Michael

Date effective: Dec. 2, 2015

Restrictions:

Voluntarily surrenders all TPP Alberta pads under his control and shall not request resumption of prescribing of medications requiring the use of a TPP Alberta pad, in any manner.

 

Lavallee, Melvyn

Date effective: March 22, 2023

Restrictions:

Type 1 and Type 2 medications monitored by the Alberta Tracked Prescription Program except for antibiotics; gabapentin, pregabalin, sustained release stimulants with a documented diagnosis of attention deficit disorder; and benzodiazepines for the treatment of epilepsy.

 

Lopez, Roehl

Date effective: March 2, 2023

Restrictions:

Restricted from prescribing Tramadol and any other Type 1 and Type 2 medications monitored by the Alberta Tracked Prescribing Program except for gabapentin, Pregabalin, antibiotics and benzodiazepines for the treatment of patients with epilepsy.

 

McAlpine, Brian Douglas

Date effective: March 11, 2022

Restrictions:

Restricted from prescribing TPP (Tracked Prescription Program) Alberta Type 1 and Type 2 medications (not including antibiotics) except for emergencies, in which case the prescription shall be for no more than a 3-day supply.

 

McPeak, Brian K.

Date effective: Aug. 28, 2019

 

McKennitt, Daniel William

Date effective: Oct. 25, 2022

Restrictions:

Prescribing of Type 1 TPP Alberta medications restricted to inpatient facilities.

 

Restrictions:

Prescribing of medications monitored by TPP Alberta (Type 1 and 2 medications) including Tramadol, with the exception of antibiotics.

 

Mentz, Helena Johanna

Date effective: May 2, 2024

Restrictions:

Prescribing restrictions apply. May maintain currently active prescriptions for Alberta TPP Type 1 and Type 2 medications initiated prior to this restriction, but is otherwise restricted from prescribing all Alberta TPP Type 1 and Type 2 medications with the exclusion of stimulants, gabapentinoids, and antibiotics.

 

Mitchell, Oluwatomi (Tomi)

Date effective: Aug. 16, 2018

Restrictions:

Restricted from prescribing Opioids.

 

Mohamed, Ataher S

Date effective: May 2, 2024

Restrictions:

Prescribing restrictions apply. Permitted to prescribe Alberta TPP Type 1 and Type 2 medications under the monitoring of and only in accordance with the direction from the CPSA Physician Prescribing Practices Program.

 

Oyama, Sonnie

Date effective: Feb. 8, 2022

Restrictions:

Type 1 and Type 2 opioid and benzodiazepine medications monitored by the Tracked Prescription Program (TPP), includes all methadone and cannabinoids but does not apply to antimicrobials, Z-drugs and stimulants tracked by the TPP.

 

Rosenstock, Carl

Date effective: Oct. 8, 2020

Restrictions:

Restricted to prescribing TPP Alberta medications to patients attached to my practice as of October 1, 2020. Restricted to prescribing opioids only to existing patients with a diagnosis of malignancy. Restricted to prescribing benzodiazepines only to existing patients with diagnoses of seizure disorders or malignancy.

 

Swart, Johan

Date effective: Dec. 14, 2017

Restrictions:

Restricted from prescribing Type 1 Medications as per the TPP Alberta program.